Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031
Hint: It's a good idea to buy the stock today.
Investing $5,000 in Eli Lilly five years ago would have resulted in a substantial return, with the stock delivering a remarkable compound annual growth rate (CAGR) of 35.86%. This growth would have transformed the initial investment into approximately $23,143. In comparison, had the money been placed in the S&P 500 since 2021, it would have only experienced a modest CAGR of 12.82%, resulting in growth to $9,139.
Although Eli Lilly's recent performance has been outstanding, it is crucial to assess if the company can continue to outperform the market in the future. Predicting the stock's value through 2031, one standout aspect of the pharmaceutical industry is the significant gains that can be realized from clinical and regulatory advancements prior to any substantial sales of leading products.
Eli Lilly has experienced this phenomenon, with tirzepatide being a prime example. As the company's most significant growth driver, tirzepatide is marketed under the brand names Mounjaro (for diabetes management) and Zepbound (for weight management in certain regions).
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
